Tempus AI, Inc. has announced a collaboration with the Abrams Research Center on Neurogenomics at Northwestern University Feinberg School of Medicine to enhance Alzheimer's disease research using artificial intelligence.

This partnership will leverage Tempus' AI-powered data analytics platform, Lens, to analyze genomic data from the Center's extensive repository.

The collaboration aims to facilitate the development of new therapeutics and accelerate the creation of innovative clinical applications that could significantly improve patient outcomes.

Ryan Fukushima, COO of Tempus, expressed excitement about the collaboration, stating that it aims to tackle complex challenges in Alzheimer's research.

David Gate, PhD, head of The Abrams Research Center, emphasized the importance of using advanced technologies to transform Alzheimer's research and develop targeted interventions.

By employing Lens' advanced AI capabilities, the teams intend to generate actionable insights that will aid in the discovery of targeted therapies.

Tempus specializes in next-generation diagnostics, offering services such as genomics, data analytics, and AI applications to personalize medicine.

The company has a workforce of approximately 2,400 employees and continues to expand its offerings in the healthcare technology sector.

The press release includes forward-looking statements regarding the collaboration's expected outcomes, cautioning that these statements involve risks and uncertainties.